Diagnostic Code 7821 · 38 CFR §4.118
DC 7821 covers the skin manifestations of collagen-vascular (connective tissue) diseases — the autoimmune disorders that produce inflammation of connective tissue throughout the body and often present first or most visibly in the skin. The main conditions in this group include systemic lupus erythematosus (SLE), with its butterfly rash across the cheeks and nose plus photosensitive skin lesions; discoid lupus erythematosus, with chronic disc-shaped scarring plaques; scleroderma, with skin tightening and pigmentation changes; dermatomyositis, with the characteristic heliotrope rash on the eyelids and Gottron papules on the knuckles; mixed connective tissue disease; and Sjögren syndrome with its dry mucocutaneous involvement. These diseases are often triggered by environmental exposures or by infections, and the skin findings can precede systemic disease by years. For veterans, recognized exposures include certain solvents, silica dust, vinyl chloride, and viral infections acquired during deployment. The VA rates DC 7821 within the dermatitis framework of 38 CFR §4.118, with severity tiers tied to body surface area affected and need for systemic therapy. When the underlying systemic disease produces impairment in other organ systems (joints, kidneys, lungs, heart), those impairments are rated separately under their respective codes.
| Rating | Criteria |
|---|---|
| 0% | Mild involvement — less than 5% of the entire body or less than 5% of exposed areas affected, AND no more than topical therapy required during the past 12-month period. |
| 10% | At least 5% but less than 20% of the entire body, OR at least 5% but less than 20% of exposed areas affected, OR intermittent systemic therapy (corticosteroids, antimalarials, methotrexate, other immunosuppressants) required for less than 6 weeks during the past 12 months. |
| 30% | 20 to 40% of the entire body or 20 to 40% of exposed areas affected, OR systemic therapy required for 6 weeks or more but not constantly during the past 12 months. |
| 60% | More than 40% of the entire body or more than 40% of exposed areas affected, OR constant or near-constant systemic therapy required during the past 12 months. |
A rheumatology diagnosis confirming the underlying collagen-vascular disease (SLE, scleroderma, dermatomyositis, etc.) is the anchor. Skin biopsy showing the characteristic histopathology supports the cutaneous diagnosis when the clinical picture is uncertain. Serology — ANA, anti-dsDNA, anti-Smith, anti-Ro, anti-La, anti-Scl-70, anti-centromere, anti-Jo-1 antibodies — characterizes the specific autoimmune disease. Treatment records documenting topical therapy, antimalarials (hydroxychloroquine), corticosteroids (oral or pulse intravenous), and other immunosuppressants establish the management burden. Photographs document the skin involvement and any disfiguring residuals. Service records documenting in-service onset of symptoms or exposure to recognized risk factors close the nexus.
No — DC 7821 captures only the cutaneous (skin) manifestations. The underlying systemic disease is rated under whichever code captures the dominant non-skin impairment. For lupus, that often means DC 7541 (lupus nephritis) when kidney involvement is dominant, DC 6532 (lupus erythematosus systemic) for the systemic features, or one of the joint codes for arthritis. For scleroderma, DC 6825 covers lung involvement and the cardiovascular and gastrointestinal codes cover those features. For dermatomyositis, the muscle injury codes (DC 5301-5323) capture the proximal muscle weakness. Filing under each applicable code produces the highest combined rating.
Yes, through several pathways. Direct service connection works when the disease was diagnosed during active duty or symptoms began during service and were documented in service treatment records. Exposure-based service connection runs through documented occupational or environmental exposures recognized in the medical literature — certain solvents, silica dust, vinyl chloride, and specific viral infections have all been associated with collagen-vascular disease onset. Some forms of lupus diagnosed within one year of separation fall within the §3.307 chronic disease presumptive framework.
A rating in continuous effect for five years or more is protected against reduction under 38 CFR §3.951 without strong evidence of sustained material improvement. Collagen-vascular diseases characteristically have flares and remissions, so a current remission does not establish sustained improvement — flares are expected to recur. Keeping a flare diary and ensuring continued rheumatology follow-up documents the chronic nature of the disease and supports the rating against reduction proposals.